NCT00645190View on ClinicalTrials.gov

A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

February 28, 2005

Conditions
Alzheimer Disease
Interventions
DRUG

Galantamine HBr

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT00645190 - A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter